Abstract | INTRODUCTION: PATIENTS AND METHODS: A review of the medical charts of consecutive NSCLC patients diagnosed between 2005 and 2016 with BM as the first relapse after curative surgery was performed. RESULTS: Among 1191 patients evaluated for EGFR mutation status, 28 patients who met the inclusion criteria were divided into 2 groups: EGFR mutation group (16 patients) and wild type group (12 patients). At BM diagnosis, the EGFR-mutation group tended to have more commonly isolated BM compared with that in the wild type group (11 of 16 vs. 3 of 12; P = .054). In the EGFR mutation group, the patients with isolated BM showed longer overall survival than those with non-isolated BM (39.6 vs. 18.7 months; P = .038). Notably, isolated BM in the EGFR mutation group was neurologically asymptomatic in 10 of the 11 patients. With regard to upfront treatment for isolated BM in the EGFR mutation group, 10 of 11 patients were treated with only cranial radiotherapy without EGFR tyrosine kinase inhibitors, but two-thirds of the patients (7 of 11; 64%) developed extracranial disease during the study period. CONCLUSION: In curatively resected NSCLC patients with EGFR mutation, isolated BM would be correlated with better prognosis, but regarded as a precursor to systemic disease. Because isolated BM can be neurologically asymptomatic, it would be important to periodically perform cranial evaluation to detect isolated BM.
|
Authors | Shinko Sadoyama, Akimasa Sekine, Hiroaki Satoh, Tae Iwasawa, Terufumi Kato, Satoshi Ikeda, Masafumi Sata, Tomohisa Baba, Erina Tabata, Yuko Minami, Kenji Nemoto, Kenji Hayashihara, Takefumi Saito, Koji Okudela, Kenichi Ohashi, Michihiko Tajiri, Takashi Ogura |
Journal | Clinical lung cancer
(Clin Lung Cancer)
Vol. 19
Issue 1
Pg. e29-e36
(01 2018)
ISSN: 1938-0690 [Electronic] United States |
PMID | 28669848
(Publication Type: Journal Article)
|
Copyright | Copyright © 2017 Elsevier Inc. All rights reserved. |
Chemical References |
- EGFR protein, human
- ErbB Receptors
|
Topics |
- Aged
- Brain Neoplasms
(mortality, secondary, surgery)
- Carcinoma, Non-Small-Cell Lung
(mortality, secondary, surgery)
- Cells, Cultured
- ErbB Receptors
(genetics)
- Female
- Humans
- Lung Neoplasms
(mortality, pathology, surgery)
- Male
- Mutation
(genetics)
- Neoplasm Metastasis
- Neoplasm Staging
- Pneumonectomy
- Survival Analysis
|